Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Harvard Business School
Johnson and Johnson
McKinsey
Dow

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Serelaxin

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Serelaxin: Patents, clinical trial progress, indications

Serelaxin is an investigational drug.

There have been 14 clinical trials for Serelaxin. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2013.

The most common disease conditions in clinical trials are Heart Failure, Liver Cirrhosis, and Hypertension, Portal. The leading clinical trial sponsors are Novartis Pharmaceuticals, Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, and University of Edinburgh.

There are two US patents protecting this investigational drug and two hundred and fifty-six international patents.

Recent Clinical Trials for Serelaxin
TitleSponsorPhase
Serelaxin To Lower Portal PressureNHS LothianPhase 2
Serelaxin To Lower Portal PressureNovartis PharmaceuticalsPhase 2
Serelaxin To Lower Portal PressureUniversity of EdinburghPhase 2

See all Serelaxin clinical trials

Clinical Trial Summary for Serelaxin

Top disease conditions for Serelaxin
Top clinical trial sponsors for Serelaxin

See all Serelaxin clinical trials

US Patents for Serelaxin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Serelaxin   Start Trial Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Start Trial
Serelaxin   Start Trial Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Serelaxin

Drugname Country Document Number Estimated Expiration Related US Patent
Serelaxin Australia 2012328780 2031-10-25   Start Trial
Serelaxin Australia 2013226031 2031-10-25   Start Trial
Serelaxin Australia 2013226034 2031-10-25   Start Trial
Serelaxin Australia 2013271436 2031-10-25   Start Trial
Serelaxin Australia 2013282411 2031-10-25   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Baxter
Boehringer Ingelheim
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.